Evidence map›Paper›PMID 40694280›Full record

ArticleInternational journal of clinical oncology2025

Clinical utility and characteristics of comprehensive genomic profiling tests in patients with gynecologic cancer: a multi-institutional survey in Kinki District, Japan.

Shinichi Terada, Tomohito Tanaka, Yoji Hisamatsu, Masato Kita, Mana Taki, Koji Yamanoi, Hiroyuki Fujita, Seiko Kato, Hisashi Kataoka, Taisuke Mori and 32 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

Shinichi TeradaDepartment of Obstetrics and Gynecology, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-machi, Takatsuki, Osaka, 569-0801, Japan.
Tomohito TanakaDepartment of Obstetrics and Gynecology, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-machi, Takatsuki, Osaka, 569-0801, Japan. tomohito.tanaka@ompu.ac.jp.ORCID http://orcid.org/0000-0003-4210-701X
Yoji HisamatsuDepartment of Obstetrics and Gynecology, Kansai Medical University, Hirakata, Osaka, Japan.
Masato KitaDepartment of Obstetrics and Gynecology, Kansai Medical University, Hirakata, Osaka, Japan.
Mana TakiDepartment of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Koji YamanoiDepartment of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroyuki FujitaDepartment of Obstetrics and Gynecology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Seiko KatoDepartment of Obstetrics and Gynecology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Hisashi KataokaDepartment of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Taisuke MoriDepartment of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hidekatsu NakaiDepartment of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan.
Noriomi MatsumuraDepartment of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan.
Hiroki NishimuraDepartment of Obstetrics and Gynecology, Shiga University of Medical Science, Shiga, Japan.
Tsukuru AmanoDepartment of Obstetrics and Gynecology, Shiga University of Medical Science, Shiga, Japan.
Naohisa MasukoDepartment of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan.
Yoshito TeraiDepartment of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan.
Madoka SurugaDepartment of Gynecology, Osaka City General Hospital, Osaka, Japan.
Makoto MurakamiDepartment of Gynecology, Osaka City General Hospital, Osaka, Japan.
Mariya KobayashiDepartment of Obstetrics and Gynecology, The University of Osaka Hospital, Osaka, Japan.
Satoshi NakagawaDepartment of Obstetrics and Gynecology, The University of Osaka Hospital, Osaka, Japan.
Hisanori MatsumotoDepartment of Obstetrics and Gynecology, National Hospital Organization, Osaka National Hospital, Osaka, Japan.
Yusuke FujikamiDepartment of Obstetrics and Gynecology, National Hospital Organization, Osaka National Hospital, Osaka, Japan.
Michihide MaedaDepartment of Gynecology, Osaka International Cancer Institute, Osaka, Japan.
Shoji KamiuraDepartment of Gynecology, Osaka International Cancer Institute, Osaka, Japan.
Kyohei NishikawaDepartment of Obstetrics and Gynecology, Nara Medical University, Nara, Japan.
Yosuke FukuiDepartment of Obstetrics and Gynecology, Nara Medical University, Nara, Japan.
Tomoko UedaDepartment of Obstetrics and Gynecology, School of Medicine, Hyogo Medical University, Hyogo, Japan.
Hiroshi TsubamotoDepartment of Obstetrics and Gynecology, School of Medicine, Hyogo Medical University, Hyogo, Japan.
Sayaka UenoSection of Translational Research, Hyogo, Japan.
Takashi ShibutaniDepartment of Gynecologic Oncology, Hyogo Cancer Center, Hyogo, Japan.
Ayame TeramotoDepartment of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan.
Yasushi MabuchiDepartment of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan.
Kazuhiko InoDepartment of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan.
Takahito MotoyamaDepartment of Obstetrics and Gynecology, Kobe City Medical Center General Hospital, Kobe, Japan.
Takuya AokiDepartment of Obstetrics and Gynecology, Kobe City Medical Center General Hospital, Kobe, Japan.
Ryo NakazawaDepartment of Obstetrics and Gynecology, Nara Prefecture General Medical Center, Nara, Japan.
Fuminori ItoDepartment of Obstetrics and Gynecology, Nara Prefecture General Medical Center, Nara, Japan.
Nao TerayamaDepartment of Obstetrics and Gynecology, NHO Osaka Minami Medical Center, Kawachinagano, Osaka, Japan.
Masanori KanemuraDepartment of Obstetrics and Gynecology, NHO Osaka Minami Medical Center, Kawachinagano, Osaka, Japan.
Azusa SakuraiDepartment of Obstetrics and Gynecology, Shiga General Hospital, Shiga, Japan.
Yumi TakaoDepartment of Obstetrics and Gynecology, Shiga General Hospital, Shiga, Japan.
Masahide OhmichiDepartment of Obstetrics and Gynecology, Osaka Medical and Pharmaceutical University, 2-7, Daigaku-machi, Takatsuki, Osaka, 569-0801, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundComprehensive genomic profiling (CGP) has been used to identify mutations in several hundred cancer-related genes. Patients may receive treatment that targets specific genetic mutations revealed by CGP. This study aimed to investigate the usefulness of CGP in gynecologic malignancies.

methodsHospital records including CGP and clinical information were reviewed from 20 institutions in the Kinki District of Japan for patients with gynecological malignancies who underwent CGP.

resultsA total of 724 patients were included, of whom 162 had cervical cancer, 157 had endometrial cancer, 327 had ovarian cancer, 29 had other cancers, and 49 had sarcomas. Actionable gene alterations were identified in 370 (51.1%). The most commonly altered genes were PIK3CA (14.4%), high loss of heterozygosity (12.4%), and high tumor mutation burden (10.9%). Matched therapy, based on actionable gene alterations, was administered to 73 patients (10.1%). Of these, 23 patients received matched therapy for a high tumor mutation burden, 10 for high microsatellite instability and BRCA1/2, six for ERBB2, and five for PIK3CA. Twenty-five patients died before receiving their CGP results. The objective response and disease control rates were 23.6% and 41.8%, respectively. Of the 122 patients to whom genetic counseling was recommended, 68 accepted.

conclusionsCGP testing for gynecological malignancies in Japan may improve therapeutic efficacy. However, several issues remain to be addressed, including the low matched therapy rate and death prior to availability of CGP test results.

Indexed as

Gene Expression ProfilingGenital Neoplasms, FemaleAdultAgedAged, 80 and overClass I Phosphatidylinositol 3-KinasesFemaleGenomicsHumansJapanMicrosatellite InstabilityMiddle AgedMutationClass I Phosphatidylinositol 3-KinasesPIK3CA protein, humanComprehensive genomic profilingGene alterationGynecologic cancerMatched therapy

Identifiers

PMID40694280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.